<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848094</url>
  </required_header>
  <id_info>
    <org_study_id>LCR-003</org_study_id>
    <nct_id>NCT00848094</nct_id>
  </id_info>
  <brief_title>Radiation Dose Escalation Study for Advanced Liver Cancer</brief_title>
  <official_title>Phase I Trial of Radiation Dose Escalation for Locally Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine the maximum tolerated dose (MTD) of
      3-dimensional conformal radiation therapy (3-DCRT)/intensity modulated radiation therapy
      (IMRT) for locally advanced hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,2 and 3 years survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm I: tumor diameter more than 5 cm and less than 10 cm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm II: tumor diameter no less than 10 cm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3DCRT/IMRT</intervention_name>
    <description>The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.</description>
    <arm_group_label>arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3DCRT/IMRT</intervention_name>
    <description>The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.</description>
    <arm_group_label>arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed or clinically diagnosed HCC

          -  Surgically unsectable or medically inoperable diseases, or surgery declined by the
             patient

          -  Solitary intrahepatic lesion with diameter bigger than 5 cm, without extrahepatic
             and/or distant metastases

          -  Associated with cirrhosis of Child-Pugh A

          -  Karnofsky performance status (KPS) of ≥ 70

          -  Normal renal function and adequate bone marrow reservation

          -  Tolerate active breathing control (ABC)

        Exclusion Criteria:

          -  Child-Pugh B or C liver cirrhosis score

          -  Previous radiotherapy to the liver

          -  Indistinct tumor boundary in CT/MRI image
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoliang Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Guoliang Jiang</name_title>
    <organization>Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>3-dimensional conformal radiation therapy (3-DCRT)</keyword>
  <keyword>intensity modulated radiation therapy (IMRT)</keyword>
  <keyword>active breathing control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

